NR3C1 rs6189: Understanding Your Glucocorticoid Sensitivity
The rs6189 variant is a single nucleotide polymorphism located within exon 2 of the NR3C1 gene, which encodes the human glucocorticoid receptor. Although rs6189 is a synonymous change (c.1088A>G) that does not alter an amino acid on its own, it occurs in high linkage disequilibrium with rs6190 to form the well-studied ER22/23EK haplotype. This genetic combination has been associated in clinical research with altered hypothalamic-pituitary-adrenal (HPA) axis dynamics and subtle differences in sensitivity to glucocorticoids such as dexamethasone.
What each genotype means
Typical Glucocorticoid Sensitivity
You carry two copies of the major A allele, representing the standard glucocorticoid receptor sequence at this locus. This genotype is associated with normal baseline receptor function and typical cortisol suppression responses in clinical tests. If you are taking corticosteroid medications, continue standard monitoring and consult your healthcare provider or pharmacist regarding any dosing questions.
Carried by approximately 70% to 80% of individuals across global populations, being most common in East Asian and African ancestries.
Modest Glucocorticoid Resistance
You carry one copy of the G allele, which is in complete linkage disequilibrium with rs6190 to form the well-studied ER22/23EK polymorphism. Research links this haplotype to slightly reduced glucocorticoid receptor transactivation and relative resistance to dexamethasone suppression, often accompanied by favorable metabolic markers such as improved insulin sensitivity. If you are prescribed glucocorticoid therapies, discuss your medication response and potential dosing considerations with your physician or pharmacist.
Carried by approximately 15% to 25% of individuals in European and admixed American populations, and is less frequent in East Asian cohorts.
Reduced Glucocorticoid Sensitivity
You carry two copies of the minor G allele, corresponding to homozygous status for the ER22/23EK haplotype. Evidence suggests this genotype contributes to diminished cellular sensitivity to cortisol and altered hypothalamic-pituitary-adrenal axis feedback. Because altered glucocorticoid sensitivity can influence drug efficacy, always consult your physician or pharmacist before making any changes to corticosteroid prescriptions.
Found in approximately 1% to 2% of European individuals and is exceedingly rare in East Asian and African populations.
Genetic Architecture of rs6189 and the NR3C1 Gene
The NR3C1 gene, positioned on chromosome 5, provides instructions for synthesizing the glucocorticoid receptor (GR). The GR protein is a ligand-activated transcription factor that controls the body's physiological response to cortisol, impacting inflammation, glucose metabolism, and stress recovery. The rs6189 variant involves an A to G nucleotide transition (c.1088A>G) within exon 2. Because this change codes for the same amino acid, it is termed synonymous. However, genetic markers rarely act in total isolation. In the human genome, rs6189 frequently travels together with a neighboring missense variant, rs6190, forming a joint functional unit termed the ER22/23EK polymorphism. Research cataloged in databases such as [dbSNP](https://www.ncbi.nlm.nih.gov/snp/rs6189) and [ClinVar](https://www.ncbi.nlm.nih.gov/clinvar/?term=rs6189) notes that this paired motif alters translational kinetics or mRNA conformation, leading to altered expression of specific glucocorticoid receptor isoforms.
Biological Mechanism and Glucocorticoid Sensitivity
When cortisol or synthetic corticosteroids like dexamethasone bind to the glucocorticoid receptor, the complex moves into the cell nucleus to modulate target gene transcription. Individuals carrying the ER22/23EK haplotype (which contains the rs6189 minor allele) have repeatedly demonstrated relative glucocorticoid resistance in physiological assays. For example, during low-dose dexamethasone suppression testing, carriers often show diminished suppression of endogenously produced cortisol compared to non-carriers. This phenomenon reflects reduced transactivation activity of the receptor complex. Interestingly, relative glucocorticoid resistance has been paradoxically correlated in observational cohorts with favorable metabolic profiles, such as improved insulin sensitivity, lower fasting blood glucose levels, and lower circulating LDL cholesterol. Diminished receptor sensitivity can partially buffer peripheral tissues from the deleterious metabolic side effects of sustained cortisol elevation.
Strength of Scientific Evidence and Clinical Health Outcomes
While biochemical laboratory assays provide a clear picture of how ER22/23EK changes receptor dynamics, the overall clinical evidence connecting rs6189 alone to broader disease endpoints remains categorized as limited and mixed. Cohort studies published across psychiatric literature, such as recurrent depressive disorder investigations indexed on [PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=rs6189), have examined whether altered HPA axis responsiveness alters susceptibility to affective disorders or antidepressant therapy. Some studies suggest carriers possess altered neuropsychiatric risk profiles or differing cognitive resilience during acute physiological stress tests, while other replication efforts show neutral results. Because many early findings relied on modest cohort sizes and showed ancestry-dependent outcomes, major medical societies have not established predictive clinical guidelines around this single marker.
Interpreting Your Results Responsibly
Discovering your rs6189 genotype can offer intriguing insights into how your body regulates stress hormones and processes corticosteroid medications, but it does not equate to a medical diagnosis. Genetic polymorphisms in NR3C1 explain only a fraction of individual variance in cortisol sensitivity, as lifestyle, chronic stress, diet, age, and epigenetic factors heavily shape HPA axis physiology. Most importantly, consumer genetic findings for rs6189 should never be used to alter, start, or discontinue any corticosteroid prescriptions. If you have questions about how you metabolize systemic or topical steroid treatments, discuss your overall medical history and dosing considerations with your physician or clinical pharmacist.
How common is this variant?
The minor allele (G) has an estimated frequency of roughly 10% to 15% across continental populations in the gnomAD database, being observed most consistently within populations of European and admixed descent while remaining less prevalent in East Asian groups.
Frequently asked questions
What is the difference between rs6189 and the ER22/23EK polymorphism?
The rs6189 variant is a specific single nucleotide change in the NR3C1 gene, while ER22/23EK refers to a two-SNP haplotype consisting of rs6189 and rs6190 located right next to each other. Because they are almost always inherited together, scientific literature often uses the terms interchangeably when discussing glucocorticoid receptor function.
Does having the rs6189 G allele cause a medical disease?
No, carrying the G allele does not directly cause any monogenic disease or medical disorder. It represents a normal human genetic variation that modestly shifts biological responsiveness to cortisol, which may slightly influence metabolic and stress markers.
Can my rs6189 genotype tell my doctor how to prescribe steroid medications?
Not currently. Although the variant alters cellular glucocorticoid sensitivity in research tests, there are no approved clinical pharmacogenomic dosing guidelines based on rs6189. You should always follow professional medical advice and consult your pharmacist regarding corticosteroid medications.
Is relative glucocorticoid resistance bad for my health?
Not necessarily. In observational epidemiological studies, relative glucocorticoid resistance linked to this variant has often been correlated with beneficial metabolic traits, such as improved insulin sensitivity, favorable lipid levels, and longevity, although neuropsychiatric findings remain mixed.
Sources & further reading
Educational information only, last refreshed 9/12/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs6189?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29